Gueorguieva Ralitza, Wu Ran, Pittman Brian, Cramer Joyce, Rosenheck Robert A, O'malley Stephanie S, Krystal John H
Department of Epidemiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Biol Psychiatry. 2007 Jun 1;61(11):1290-5. doi: 10.1016/j.biopsych.2006.09.038. Epub 2007 Jan 16.
The heterogeneity of clinical findings in studies evaluating the efficacy of naltrexone in the treatment of alcohol dependence has led to growing efforts to explore novel approaches to data analysis. The objective of this study was to identify distinct trajectories of daily drinking over time in two negative clinical trials and to determine whether naltrexone affected the probability to follow a particular trajectory.
The Veterans Affairs (VA) Cooperative Study #425 and the Women's Naltrexone Study failed to demonstrate efficacy on primary outcome variables. Separately for each study, we analyzed daily indicators of any drinking and heavy drinking using a semiparametric group-based approach.
We estimated three distinct trajectories of daily drinking (both any and heavy drinking) which we described as "abstainer," "sporadic drinker," and "consistent drinker." Naltrexone doubled the odds of following the abstainer trajectory instead of the consistent drinker trajectory but did not significantly change the odds of following the abstainer trajectory as contrasted with the sporadic drinker trajectory.
Naltrexone may have a clinically meaningful effect for alcohol-dependent patients with a high chance of consistent drinking, even in studies where it failed to show efficacy in planned analyses.
在评估纳曲酮治疗酒精依赖疗效的研究中,临床结果的异质性促使人们越来越努力探索新的数据分析方法。本研究的目的是在两项阴性临床试验中确定随时间变化的每日饮酒的不同轨迹,并确定纳曲酮是否会影响遵循特定轨迹的概率。
退伍军人事务部(VA)合作研究#425和女性纳曲酮研究未能在主要结局变量上证明疗效。对于每项研究,我们使用基于半参数分组的方法分析了任何饮酒和重度饮酒的每日指标。
我们估计了每日饮酒(包括任何饮酒和重度饮酒)的三种不同轨迹,我们将其描述为“戒酒者”、“偶尔饮酒者”和“持续饮酒者”。与持续饮酒者轨迹相比,纳曲酮使遵循戒酒者轨迹的几率增加了一倍,但与偶尔饮酒者轨迹相比,并未显著改变遵循戒酒者轨迹的几率。
即使在计划分析中未能显示疗效的研究中,纳曲酮对于有持续饮酒高可能性的酒精依赖患者可能具有临床意义的效果。